Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Vir Biotechnology, Inc.

http://www.vir.bio

Latest From Vir Biotechnology, Inc.

Lilly Claims Proof Of Concept For Neutralizing Antibodies In COVID-19 Therapy

Analysts called the interim data from a Phase II study of LY-CoV555 mixed, but Lilly insists that it has demonstrated a therapeutic role for neutralizing antibodies in fighting the novel coronavirus.

Coronavirus COVID-19 Clinical Trials

Silence Therapeutics Continues Transformation, Improves US Visibility

The UK's Silence Therapeutics is moving its candidate products into early clinical studies in cardiovascular diseases and improving its visibility with a NASDAQ listing.


Financing Gene Therapy

RNAi Partners Vie To Lead Race To Cure Hepatitis B

At EASL 2020, four partnerships updated RNA-interference or antisense efforts to reduce hep B surface antigen, believed to lead to functional cure of the virus. One analyst sees J&J/Arrowhead as the early leader.

Clinical Trials Business Strategies

Regeneron and Roche Await Data On Potential COVID-19 Blockbuster

Results from COVID-19 antibody therapies from Regeneron and Lilly and several other developers are expected soon – but their window of opportunity could be short.

Biologics Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Humabs BioMed SA
UsernamePublicRestriction

Register